Cynosure Announces Schedule of Upcoming Investor Conferences

Wednesday, June 4, 2008 General News J E 4
WESTFORD, Mass., June 3 Cynosure, Inc.(Nasdaq: CYNO), a leading developer and manufacturer of a broad array oflight-based aesthetic treatment systems, today announced that President andChief Executive Officer Michael Davin and Chief Financial Officer TimothyBaker will discuss the company's business outlook, growth strategy and recentfinancial results at the following investor conferences this month:

Investors interested in listening to the live webcasts of thesepresentations should log on to the "Investor Relations" section of Cynosure'swebsite,, and click on the link labeled "Events." Thepresentations also will be archived on the company's website.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that areused by physicians and other practitioners to perform non-invasive andminimally invasive procedures to remove hair, treat vascular lesions,rejuvenate skin through the treatment of shallow vascular and pigmentedlesions, laser lipolysis and temporarily reduce the appearance of cellulite.Cynosure's products include a broad range of laser and other light-basedenergy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, aswell as intense pulsed light. Cynosure was founded in 1991. For corporate orproduct information, contact Cynosure at 800-886-2966, or On Thursday, June 12, the company will present at the 7th Annual Needham & Company Biotechnology and Medical Technology Conference in New York City. The presentation is scheduled to begin at 10:00 a.m. ET. -- On Wednesday, June 25, Cynosure will present at the Jefferies 2nd Annual Healthcare Conference in New York City. The presentation is scheduled to begin at 3:45 p.m. ET.

SOURCE Cynosure, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Cynosure Announces Schedule of Upcoming Investor C...
Huifeng Bio-Pharmaceutical (HFGB) Provides Update ...